Cavernous angioma risk factors: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Cavernous angioma}} {{CMG}} Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing. ==Gene...")
 
No edit summary
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Cavernous angioma}}
{{Cavernous angioma}}
{{CMG}}
{{CMG}}; {{AE}}


Please help WikiDoc by adding more content here. It's easy!  Click  [[Help:How_to_Edit_a_Page|here]]  to learn about editing.
==Overview==
Family history increases the risk of having cavernous angioma. Genetic testing is recommended for the pathogenic variants of cavernous angioma (''KRIT1'', ''CCM2'', and ''PDCD10'').


==Genetic Risk Factors==
==Risk Factors==
Familial forms of CCM occur at three known genetic loci. The gene for CCM1 encodes ''KRIT1'' (krev interaction trapped 1) and has been found to bind to ICAP1alpha (integrin cytoplasmic domain associated protein alpha), a beta1 [[integrin]] associated protein. The gene for ''CCM2'' encodes a novel protein named "malcavernin" that contains a phosphotyrosine (PTB) binding domain. The exact biological function of CCM2 is not clear. Recently, it has been shown that CCM1 and CCM2 proteins as well as ICAP1alpha form a macromolecular complex in the cell. In addition, it appears that CCM2 protein may function as a scaffolding protein for [[MAP kinases]] that are essential in p38 activation responding to osmotic stress including MEKK3 and MKK3. It also binds to [[Rac]] and [[actin]]. Therefore, CCM2 protein is also called OSM (osmosensing scaffold for MEKK3). The ''CCM3'' gene was the most recent CCM gene identified. CCM3 was known as PDCD10 (programmed cell death 10), which was initially identified as a gene that is up-regulated during the induction of [[apoptosis]] (cell death) in TF-1, a human [[myeloid]] cell line. The precise role of the PDCD10 protein in the CCM pathway that has been established to this point has not yet been determined. Research is ongoing to determine the function and properties of all three CCM gene products as well as the reaction pathways in which they are involved.
Familial forms of CCM occur at three known genetic loci. The gene for CCM1 encodes ''KRIT1'' (krev interaction trapped 1) and has been found to bind to ICAP1alpha (integrin cytoplasmic domain associated protein alpha), a beta1 [[integrin]] associated protein. The gene for ''CCM2'' encodes a novel protein named "malcavernin" that contains a phosphotyrosine (PTB) binding domain. The exact biological function of CCM2 is not clear. Recently, it has been shown that CCM1 and CCM2 proteins as well as ICAP1alpha form a macromolecular complex in the cell. In addition, it appears that CCM2 protein may function as a scaffolding protein for [[MAP kinases]] that are essential in p38 activation responding to osmotic stress including MEKK3 and MKK3. It also binds to [[Rac]] and [[actin]]. Therefore, CCM2 protein is also called OSM (osmosensing scaffold for MEKK3). The ''CCM3'' gene was the most recent CCM gene identified. CCM3 was known as PDCD10 (programmed cell death 10), which was initially identified as a gene that is up-regulated during the induction of [[apoptosis]] (cell death) in TF-1, a human [[myeloid]] cell line. The precise role of the PDCD10 protein in the CCM pathway that has been established to this point has not yet been determined. Research is ongoing to determine the function and properties of all three CCM gene products as well as the reaction pathways in which they are involved.



Revision as of 12:54, 23 February 2022

Cavernous angioma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Cavernous angioma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

CT

MRI

MRA

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Cavernous angioma risk factors On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cavernous angioma risk factors

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cavernous angioma risk factors

CDC on Cavernous angioma risk factors

Cavernous angioma risk factors in the news

Blogs on Cavernous angioma risk factors

Directions to Hospitals Treating Cavernous angioma

Risk calculators and risk factors for Cavernous angioma risk factors

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

Family history increases the risk of having cavernous angioma. Genetic testing is recommended for the pathogenic variants of cavernous angioma (KRIT1, CCM2, and PDCD10).

Risk Factors

Familial forms of CCM occur at three known genetic loci. The gene for CCM1 encodes KRIT1 (krev interaction trapped 1) and has been found to bind to ICAP1alpha (integrin cytoplasmic domain associated protein alpha), a beta1 integrin associated protein. The gene for CCM2 encodes a novel protein named "malcavernin" that contains a phosphotyrosine (PTB) binding domain. The exact biological function of CCM2 is not clear. Recently, it has been shown that CCM1 and CCM2 proteins as well as ICAP1alpha form a macromolecular complex in the cell. In addition, it appears that CCM2 protein may function as a scaffolding protein for MAP kinases that are essential in p38 activation responding to osmotic stress including MEKK3 and MKK3. It also binds to Rac and actin. Therefore, CCM2 protein is also called OSM (osmosensing scaffold for MEKK3). The CCM3 gene was the most recent CCM gene identified. CCM3 was known as PDCD10 (programmed cell death 10), which was initially identified as a gene that is up-regulated during the induction of apoptosis (cell death) in TF-1, a human myeloid cell line. The precise role of the PDCD10 protein in the CCM pathway that has been established to this point has not yet been determined. Research is ongoing to determine the function and properties of all three CCM gene products as well as the reaction pathways in which they are involved.

Mutations in these three genes account for 70 to 80 percent of all cases of cerebral cavernous malformations. The remaining 20 to 30 percent of cases may be due to other, still unidentified, genes.

References